Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
80.91 USD | -1.53% | -8.71% | -16.09% |
Financials (USD)
Sales 2024 * | 2.74B | Sales 2025 * | 3.1B | Capitalization | 15.59B |
---|---|---|---|---|---|
Net income 2024 * | 361M | Net income 2025 * | 491M | EV / Sales 2024 * | 5.39 x |
Net cash position 2024 * | 812M | Net cash position 2025 * | 1.37B | EV / Sales 2025 * | 4.59 x |
P/E ratio 2024 * |
45
x | P/E ratio 2025 * |
32.4
x | Employees | 3,401 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.16% |
Latest transcript on BioMarin Pharmaceutical Inc.
1 day | -1.53% | ||
1 week | -9.59% | ||
Current month | -7.36% | ||
1 month | -8.69% | ||
3 months | -11.84% | ||
6 months | +0.30% | ||
Current year | -16.09% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
Kevin Eggan
CTO | Chief Tech/Sci/R&D Officer | - | 20-10-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Director/Board Member | 70 | 05-05-15 | |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.45% | 1 M€ | 0.00% | - | |
1.79% | 0 M€ | 0.00% | - | |
1.59% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 80.91 | -1.53% | 2,257,105 |
24-04-25 | 82.17 | -9.90% | 7,884,498 |
24-04-24 | 91.2 | -0.93% | 1,599,632 |
24-04-23 | 92.06 | +2.87% | 1,299,078 |
24-04-22 | 89.49 | +0.97% | 1,257,361 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.09% | 15.59B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.27% | 29.48B | |
+57.86% | 25.43B | |
-17.69% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- BMRN Stock